Singapore Clinical Trial: Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children with Hypochondroplasia: ACCEL OLE

Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children with Hypochondroplasia: ACCEL OLE'. The following are the other relevant details related to the trial:

Therapeutic Area: Other (Paediatric Medicine)

Trial Centre(s): KK Women's & Children's Hospital

Trial Status: NA

Principal Investigator(s): Dr Goh Lay Kuan Jeannette

Published by HT Digital Content Services with permission from Health Daily Digest....